Ares Capital Corporation (ARCC) Stock Price Today
Key Stats
- $13.76BMarket Cap
- 7,671,849Volume
- FinancialsSector
- $21.0252W High
- $17.4552W Low
- 125 DaysTypical Hold Time
- $29.15BEnterprise Value
- 10.05%Div Yield
- 3% Sell | 97% BuyTrading Activity
Track Ares Capital Corporation (ARCC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Ares Capital Corporation has traded between a low of $17.45 and a high of $21.02, highlighting its annual price range. Buy and sell Ares Capital Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Most Recent News
One sizable IPO, one direct listing, and one SPAC debuted; Oura delays multibillion-dollar IPO.
This week saw the debut of one sizable IPO, one direct listing, and one SPAC, alongside initial filings from three small IPOs, one direct listing, and six SPACs. Notably, Oura postponed its planned multibillion-dollar IPO, marking a significant devel...
Municipal bonds and high-yield muni-bond funds sharply sold off, raising risks and tax concerns.
Municipal bonds experienced a significant selloff over the past month, with high-yield municipal bond closed-end funds (CEFs) yielding over 8% dropping even more sharply. The article highlights data on five top big-yield muni-bond CEFs, focusing part...
Arrowhead's plozasiran shows strong results to challenge Ionis in severe hypertriglyceridemia market
Arrowhead Pharmaceuticals is set to compete with Ionis in treating severe hypertriglyceridemia (sHTG) using plozasiran, which benefits from a $215 million priority review voucher enabling a faster market launch. Phase III trials SHASTA-3 and SHASTA-4...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.